Effects of a novel individualized digital cognitive training on ADHD characteristics, quality of life, and cognitive functioning in adults with ADHD: A randomized controlled trial.

J Psychiatr ResMay 12, 2026 (epub)
Clinical ResearchPsychiatry

Moritz Bergmann, Julia Schröfel, Laura Zimmermann et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effects of the digital cognitive training application 'NeuroNation MED' on adults with ADHD. The study involved 77 participants and found significant improvements in psychological quality of life and subjective cognitive ratings, with effect sizes ranging from 0.47 to 0.94. However, no significant changes were observed in objective cognitive performance or ADHD characteristics.

Key findings

  • Participants in the training group showed significant improvements in psychological quality of life compared to controls.
  • Subjective ratings indicated perceived gains in attention, memory, language, and executive functions with effect sizes of 0.47 to 0.94.
  • No significant changes were observed in objective neuropsychological test performance or ADHD characteristics.

Why it matters

Understanding the impact of digital cognitive training on perceived cognitive functioning and quality of life can inform non-pharmacological treatment options for adults with ADHD, addressing both subjective and objective aspects of the condition.

Source

PubMed · PMID 42142506

Published in J Psychiatr Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.